SATELLOS Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the
SATELLOS Announces Development Candidate
- SAT-3153 Designated for pre-IND Studies - TORONTO, January 03, 2023 – Satellos Bioscience Inc.
SATELLOS Announces Q3 2022 Financial Results and Operational Highlights
SATELLOS BIOSCIENCE ANNOUNCES Q3 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS TORONTO, November 23, 2022 –
SATELLOS Announces Advancement of Compounds to Next Stage of Development
-Proof of concept studies to be completed by YE- TORONTO, November 03, 2022 – Satellos
SATELLOS to present preliminary preclinical proof of concept data for an additional rare disease at World Muscle Society Meeting
Satellos Bioscience Inc. to present preliminary preclinical proof of concept data for an additional rare
SATELLOS INC. Announces Licensing of Formulation Technology and Expand Collaboration with NW PHARMATECH LTD.
TORONTO, October 6, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), is
SATELLOS Announces OTCQB Listing in the United States
SATELLOS BIOSCIENCE ANNOUNCES OTCQB LISTING IN THE UNITED STATES TORONTO, October 6, 2022 – Satellos
SATELLOS Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
SATELLOS Announces Closing of Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS
SATELLOS Announces the Filing of Final Short Form Prospectus for Proposed Offering of Units
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS